NaNotics Receives Investment From LifeSpan Vision Ventures

▤ Summary

The amount of the deal was not disclosed. The company intends to use the funds to continue to expand its development efforts. Led by Lou Hawthorne, CEO, NaNotics is a preclinical-stage biopharmaceutical company which is developing NaNots™, subtractive nanoparticles that treat disease by capturing and clearing pathogenic molecules from blood. It differs from traditional drug therapies in their ability to deplete soluble targets without interacting with the membrane forms of the same target, a feat that is typically beyond the reach of conventional drugs.

▦ Linked Companies